Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates St. Louis, November 10, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported bus
How this was made
The 30-second read
Why it matters
The Q3 results show revenue growth but widening losses, while the new financing aims to stabilize cash flow.
Market read
The earnings release provides fresh data for traders in the medical‑device niche, with potential short‑term downside but a financing cushion.
What to watch
Potential upside from the recent acquisition of Robocath and the Canon collaboration, which may drive future growth beyond the current quarter.
Stereotaxis Q3 2026 revenue rose 20% to $8,925 thousand on system sales, while adjusted operating loss widened to $(5.1) million and cash fell to $3,976 thousand before a convertible note financing
Total revenue grew 20% year over year and system revenue rose 60%, but recurring revenue declined 4% sequentially, adjusted operating expenses rose to $9.1 million from $6.6 million, GAAP net loss was essentially unchanged, and cash of $3,976 thousand at September 30, 2026 required a convertible note financing of up to $24 million.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue (Q3 2026)GAAP | $8.93M | 16% | 20% |
| Systems revenue (Q3 2026)GAAP | $2.98M | – | 60% |
| Disposables, service and accessories revenue, recurring revenue (Q3 2026)GAAP | $5.95M | declined 4% | 6% |
| Total cost of revenue (Q3 2026)GAAP | $4.97M | – | – |
| Cost of revenue, systems (Q3 2026)GAAP | $2.52M | – | – |
| Cost of revenue, disposables, service and accessories (Q3 2026)GAAP | $2.44M | – | – |
| Gross margin, dollars (Q3 2026)GAAP | $3.96M | – | – |
| Gross margin, percent of revenue (Q3 2026)GAAP | 45% of revenue | – | – |
| Recurring revenue gross margin (Q3 2026)GAAP | 59% | – | – |
| System gross margin (Q3 2026)GAAP | 15% | – | – |
| Research and development (Q3 2026)GAAP | $3.52M | – | – |
| Sales and marketing (Q3 2026)GAAP | $2.86M | – | – |
| General and administrative (Q3 2026)GAAP | $4.05M | – | – |
| Total operating expenses (Q3 2026)GAAP | $10.43M | – | – |
| Adjusted operating expenses, excluding non-cash charges (Q3 2026)non-GAAP | $9.1M | – | – |
| Operating loss (Q3 2026)GAAP | −$6.47M | – | – |
| Adjusted operating loss, excluding non-cash charges (Q3 2026)non-GAAP | −$5.1M | – | – |
| Interest expense (Q3 2026)GAAP | −$44K | – | – |
| Interest income (Q3 2026)GAAP | $33K | – | – |
| Net loss (Q3 2026)GAAP | −$6.48M | – | – |
| Adjusted net loss, excluding non-cash charges (Q3 2026)non-GAAP | −$5.2M | – | – |
| Net loss attributable to common stockholders (Q3 2026)GAAP | −$6.80M | – | – |
| Cumulative dividend on convertible preferred stock (Q3 2026)GAAP | −$316K | – | – |
| Net loss per share, basic (Q3 2026)GAAP | $(0.07) | – | – |
| Net loss per share, diluted (Q3 2026)GAAP | $(0.07) | – | – |
| Negative cash flow (Q3 2026)other | −$6.5M | – | – |
| Negative cash flow associated with core Stereotaxis business (Q3 2026)other | −$2.6M | – | – |
| Payments associated with acquisition of Robocath (Q3 2026)other | −$3.9M | – | – |
| Total revenue (nine months ended Sep 30, 2026)GAAP | $22.89M | – | – |
| Systems revenue (nine months ended Sep 30, 2026)GAAP | $5.77M | – | – |
| Disposables, service and accessories revenue (nine months ended Sep 30, 2026)GAAP | $17.11M | – | – |
| Total cost of revenue (nine months ended Sep 30, 2026)GAAP | $10.65M | – | – |
| Gross margin, dollars (nine months ended Sep 30, 2026)GAAP | $12.24M | – | – |
| Research and development (nine months ended Sep 30, 2026)GAAP | $8.31M | – | – |
| Sales and marketing (nine months ended Sep 30, 2026)GAAP | $8.07M | – | – |
| General and administrative (nine months ended Sep 30, 2026)GAAP | $12.88M | – | – |
| Total operating expenses (nine months ended Sep 30, 2026)GAAP | $29.26M | – | – |
| Operating loss (nine months ended Sep 30, 2026)GAAP | −$17.02M | – | – |
| Net loss (nine months ended Sep 30, 2026)GAAP | −$16.81M | – | – |
| Net loss attributable to common stockholders (nine months ended Sep 30, 2026)GAAP | −$17.75M | – | – |
| Net loss per share, basic (nine months ended Sep 30, 2026)GAAP | $(0.18) | – | – |
| Net loss per share, diluted (nine months ended Sep 30, 2026)GAAP | $(0.18) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| SystemsThe filing states that system revenue benefited from partial revenue recognition on the shipment of the first GenesisX system sold in the United States, the first Genesis system sold in China, and the first full quarter of Synchrony system sales. Prior-year system revenue was $1.9 million, and system gross margin was 15%. | $2,976 thousand (Q3 2026) | – | 60% |
| Disposables, service and accessories (recurring revenue)The company states that recurring revenue reflects increasing contributions from its portfolio of robotically-navigated catheters, countered by general procedural pressure due to limited catheter supply. Recurring revenue gross margin was 59%. The company also reports a backlog of approximately $1.9 million in disposable orders not converted to revenue because of supply constraints. | $5,949 thousand (Q3 2026) | declined 4% | 6% |
Going forward (no period specified in filing) outlook
- Operating expensesAdjusted operating expenses, excluding non-cash and one-time items, are expected to approximate $8 million per quarter going forward
- NoteCompany expects growing recurring revenue and more consistent capital sales in the coming quarters
- NoteNear-term milestones cited by the company: installing the first commercial GenesisX systems and resolving the supply constraints with MAGiC
- NoteCompany states that growth in revenue combined with stable operating expenses provides a pathway to cash-flow profitability within the next year
Capital returns
- No share repurchase or common dividend is printed in the filing
- Cumulative dividend on convertible preferred stock: $(316) thousand in Q3 2026 vs $(322) thousand in Q3 2025, and $(941) thousand in nine months 2026 vs $(953) thousand in nine months 2025
What drove it
- Company explanation for system revenue growth: partial revenue recognition on the first GenesisX system sold in the United States, the first Genesis system sold in China, and the first full quarter of Synchrony system sales
- Company explanation for recurring revenue: increasing contributions from robotically-navigated catheters, countered by general procedural pressure due to limited catheter supply
- Company explanation for the increase in adjusted operating expenses to $9.1 million from $6.6 million: one-time acquisition transaction costs and the absorption of Robocath operating expense
- Company explanation for the increase in adjusted operating loss and adjusted net loss: predominantly one-time transaction costs and the absorption of Robocath operating expense
- Company explanation for gross margin levels: fixed overhead allocated over low production volume, affecting both recurring and system revenue
- Operating expenses of $10,427 thousand included $1.3 million in non-cash charges for stock compensation expense, mark-to-market adjustment for acquisition related contingent earnout consideration, and amortization of acquired intangible assets, as stated by the company
Concerns
- Cash and cash equivalents fell to $3,976 thousand at September 30, 2026, and the company announced a convertible note financing of up to $24 million, with $12 million available only after regulatory milestones
- Recurring revenue declined 4% sequentially, which the company attributes to limited catheter supply and procedural pressure
- The company reports approximately $1.9 million in disposable orders entering the fourth quarter that were not converted to revenue because of supply constraints
- Adjusted operating loss widened to $(5.1) million from $(2.5) million in the prior-year third quarter
- Gross margin of 15% on system revenue and 59% on recurring revenue, with the company citing fixed overhead over low production volume
- Long-term contingent consideration rose to $14,928 thousand from $4,724 thousand at December 31, 2025, and goodwill rose to $29,276 thousand from $3,764 thousand, following the Robocath acquisition
- Nine-month operating loss of $(17,020) thousand was larger than the $(16,463) thousand in the prior-year period, and nine-month research and development rose to $8,310 thousand from $6,673 thousand
What to watch
- Installation of the first commercial GenesisX systems, which the company names as a near-term milestone
- Resolution of the supply constraints with MAGiC and conversion of the approximately $1.9 million in disposable backlog to revenue
- Whether adjusted operating expenses approximate $8 million per quarter, as the company guides
- Regulatory milestones that would allow the additional $12 million draw under the convertible note financing
- Whether recurring revenue growth resumes after the 4% sequential decline in Q3 2026
- Progress toward the company's stated pathway to cash-flow profitability within the next year
Balance sheet and cash flow
- Cash and cash equivalents at September 30, 2026: $3,976 thousand (company text: $4.0 million) vs $13,421 thousand at December 31, 2025
- Total assets: $82,112 thousand at September 30, 2026 vs $52,251 thousand at December 31, 2025
- Goodwill: $29,276 thousand at September 30, 2026 vs $3,764 thousand at December 31, 2025
- Total liabilities: $55,581 thousand at September 30, 2026 vs $33,530 thousand at December 31, 2025
- Total stockholders' equity: $21,360 thousand at September 30, 2026 vs $13,481 thousand at December 31, 2025
- Long-term debt: $1,922 thousand and current portion of long-term debt: $548 thousand at September 30, 2026; no debt is printed at December 31, 2025
- Long-term contingent consideration: $14,928 thousand at September 30, 2026 vs $4,724 thousand at December 31, 2025
- Negative cash flow for Q3 2026 was $(6.5) million, of which $(2.6) million was associated with the core Stereotaxis business and $(3.9) million were payments associated with the acquisition of Robocath (company statement)
- Convertible note financing announced with the results: up to $24 million, with an initial upfront closing of $12 million and an additional $12 million draw at Stereotaxis' option following certain regulatory milestones
- Company states that pro forma cash balance including the financing proceeds would be $16 million, with access to an additional $12 million, for total availability of $28 million
Analysis
Stereotaxis reported third-quarter 2026 total revenue of $8,925 thousand, up 20% from $7,464 thousand a year earlier and up 16% from $7.7 million in the second quarter, according to the company. The growth came from systems, where revenue rose to $2,976 thousand from $1,861 thousand (up 60%). The company attributes this to partial revenue recognition on the first GenesisX system sold in the United States, the first Genesis system sold in China, and the first full quarter of Synchrony system sales. Recurring revenue, which corresponds to the disposables, service and accessories line, was $5,949 thousand, up 6% year over year but down 4% sequentially. The company links the sequential decline to limited catheter supply and reports a backlog of approximately $1.9 million in disposable orders it could not convert in the quarter.
Margins were weak. Gross margin was 45% of revenue, with recurring revenue gross margin at 59% and system gross margin at 15%. The company states that both lines are affected by fixed overhead allocated over low production volume. Gross margin dollars were $3,956 thousand compared with $4,101 thousand a year earlier. Operating expenses were $10,427 thousand, essentially flat with $10,658 thousand in the prior-year quarter, but this total includes $1.3 million of non-cash charges. Excluding those charges, adjusted operating expenses rose to $9.1 million from $6.6 million, which the company attributes to one-time acquisition transaction costs and the absorption of Robocath operating expense. On the same basis, adjusted operating loss widened to $(5.1) million from $(2.5) million, and adjusted net loss to $(5.2) million from $(2.4) million. GAAP operating loss of $(6,471) thousand and net loss of $(6,482) thousand were close to the prior-year quarter.
The balance sheet shows the effect of the Robocath acquisition. Goodwill increased to $29,276 thousand from $3,764 thousand at December 31, 2025, and long-term contingent consideration increased to $14,928 thousand from $4,724 thousand. Cash and cash equivalents were $3,976 thousand at September 30, 2026, down from $13,421 thousand at year end. Third-quarter negative cash flow was $(6.5) million, of which $(3.9) million were payments associated with the Robocath acquisition. The company announced a convertible note financing of up to $24 million, with $12 million at closing and a further $12 million at its option after regulatory milestones, and states that pro forma cash would be $16 million. The filing does not print the note's interest rate, maturity or conversion terms, so those cannot be assessed from this document.
Management's forward view is qualitative. The company expects growing recurring revenue and more consistent capital sales, names the installation of the first commercial GenesisX systems and the resolution of MAGiC supply constraints as near-term milestones, and expects adjusted operating expenses of approximately $8 million per quarter. It states that revenue growth with stable operating expenses provides a pathway to cash-flow profitability within the next year. No revenue, margin or tax guidance is given, and no prior outlook was provided for comparison. The figures in this release support the company's claim of system revenue growth and a rising cost base, but the path to profitability depends on supply resolution and on drawing the second tranche of financing.
Management, verbatim
Our near-term priority is to drive forward two major business model transformations.
David Fischel, Chairman and Chief Executive Officer
We entered the fourth quarter with a backlog of approximately $1.9 million in disposable orders we did not convert to revenue because of supply constraints.
David Fischel, Chairman and Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter (Q2 2026) values for individual line items, other than total revenue stated as $7.7 million and the sequential changes printed for total and recurring revenue
- Prior-year and sequential change figures for gross margin percentage, recurring revenue gross margin and system gross margin
- Prior-year percentage change for gross margin dollars, total operating expenses, research and development, sales and marketing, general and administrative and operating loss, as not printed
- Sequential change for system revenue and for operating expense lines
- Year-over-year changes for nine-month line items, which are not printed
- Prior-year figures for adjusted operating expenses, adjusted operating loss and adjusted net loss are printed, but their percentage changes are not
- Prior period (Q2 2026) figures for adjusted metrics and for cash flow
- Numeric revenue, gross margin, operating expense or tax guidance and any guidance period beyond the qualitative outlook
- Previous outlook, so no vs_prior_guidance comparison is possible
- Interest rate, maturity, conversion price and other terms of the convertible note financing (Item 2.03)
- Details of the unregistered equity sales referenced under Item 3.02
- Purchase price and consideration of the Robocath acquisition (Item 1.01 and 2.01 context)
- Operating cash flow and free cash flow totals as separate line items
- Share price reaction, consensus estimates and analyst expectations
- Cash flow statement and detailed net change in cash for the period
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Stereotaxis is a small‑cap developer of robotic systems for endovascular procedures, recently expanding its product line and completing an acquisition.
Ticker impact
Stereotaxis filed an 8‑K reporting Q3 2026 results, including revenue of $8.9 M, a $5.1 M adjusted operating loss and a $24 M convertible note financing.
likely pressure as investors price the operating loss and cash‑flow deficit despite the convertible note credit.
The disclosed loss and modest revenue growth are material for this micro‑cap; the financing mitigates but does not offset the negative earnings surprise.
Market effects
Highlights challenges in the surgical‑robotics sector with supply constraints affecting recurring revenue.
Limited to U.S. and China markets where the GenesisX and Genesis systems were shipped.
Modest, primarily affecting niche medical‑device investors.
Counterpoint
The convertible note financing and backlog of disposable orders could support a short‑term bounce if investors focus on liquidity relief.
Key entities
- companyStereotaxis, Inc.
Medical‑device maker reporting Q3 2026 results.
- companyRobocath
Acquired firm whose operating expenses now affect Stereotaxis.
- companyCanon
Partner announced for collaboration.


